NCT06195267 - Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI) | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Aortic DissectionSystemic Inflammatory Response SyndromeCardiovascular Diseases (CVD)

Interventions

DRUG

Sivelestat

The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.

DRUG

Blank control

Patients only received standard treatment and care.

Trial Locations (2)

Unknown

RECRUITING

Beijing Anzhen Hospital, Beijing

RECRUITING

The First Affiliated Hospital of Nanjing Medical University and Jiang ye-fan, Nanjing